Steven N Hart1, Xiao-Bo Zhong. 1. University of Kansas Medical Center, Department of Pharmacology, Toxicology, and Therapeutics, 3901 Rainbow Boulevard, Kansas City, Kansas 66160, USA.
Abstract
BACKGROUND: Cytochrome P450 oxidoreductase (POR) is the only electron donor for all microsomal cytochrome P450 monooxygenases (CYP), some of which are phase I drug-metabolizing enzymes, responsible for oxidation of more than 80% of drugs. OBJECTIVES: To provide a more thorough understanding of the genetic factors influencing drug metabolism, we address the role of genetic polymorphisms in the POR gene, and their implications for drug metabolism and cytotoxicity. METHODS: The scope of this review is intended to cover polymorphisms currently identified in the POR gene, assess their functional significance on POR activity, and address their impact on CYP-mediated drug metabolism. POR is also responsible for directly metabolizing several anticancer prodrugs via a 1-electron reduction reaction, so the effect of POR polymorphisms on the direct bioactivation of drugs is also considered. RESULTS/ CONCLUSION: POR is a polymorphic enzyme that can affect CYP-mediated drug metabolism as well as direct bioactivation of prodrugs. Genetic polymorphisms in the POR gene may help to explain altered drug-metabolizing phenotypes.
BACKGROUND: Cytochrome P450 oxidoreductase (POR) is the only electron donor for all microsomal cytochrome P450 monooxygenases (CYP), some of which are phase I drug-metabolizing enzymes, responsible for oxidation of more than 80% of drugs. OBJECTIVES: To provide a more thorough understanding of the genetic factors influencing drug metabolism, we address the role of genetic polymorphisms in the POR gene, and their implications for drug metabolism and cytotoxicity. METHODS: The scope of this review is intended to cover polymorphisms currently identified in the POR gene, assess their functional significance on POR activity, and address their impact on CYP-mediated drug metabolism. POR is also responsible for directly metabolizing several anticancer prodrugs via a 1-electron reduction reaction, so the effect of POR polymorphisms on the direct bioactivation of drugs is also considered. RESULTS/ CONCLUSION:POR is a polymorphic enzyme that can affect CYP-mediated drug metabolism as well as direct bioactivation of prodrugs. Genetic polymorphisms in the POR gene may help to explain altered drug-metabolizing phenotypes.
Authors: Junling Yang; Minxia M He; Wei Niu; Steven A Wrighton; Li Li; Yang Liu; Chuan Li Journal: Br J Clin Pharmacol Date: 2012-02 Impact factor: 4.335
Authors: Christopher C Marohnic; Warren J Huber Iii; J Patrick Connick; James R Reed; Karen McCammon; Satya P Panda; Pavel Martásek; Wayne L Backes; Bettie Sue S Masters Journal: Arch Biochem Biophys Date: 2011-06-28 Impact factor: 4.013
Authors: David S Riddick; Xinxin Ding; C Roland Wolf; Todd D Porter; Amit V Pandey; Qing-Yu Zhang; Jun Gu; Robert D Finn; Sebastien Ronseaux; Lesley A McLaughlin; Colin J Henderson; Ling Zou; Christa E Flück Journal: Drug Metab Dispos Date: 2012-10-19 Impact factor: 3.922
Authors: Dennis A Hesselink; Rachida Bouamar; Laure Elens; Ron H N van Schaik; Teun van Gelder Journal: Clin Pharmacokinet Date: 2014-02 Impact factor: 6.447